1-phenyl-2-decanoylamino-3-morpholino-1-propanol has been researched along with cycloserine in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (50.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Inokuchi, J; Radin, NS; Shukla, A; Shukla, GS | 1 |
Meredith, FI; Rentz, SS; Riley, RT; Showker, JL | 1 |
2 other study(ies) available for 1-phenyl-2-decanoylamino-3-morpholino-1-propanol and cycloserine
Article | Year |
---|---|
Rapid kidney changes resulting from glycosphingolipid depletion by treatment with a glucosyltransferase inhibitor.
Topics: Animals; Brain; Ceramides; Cycloserine; Galactosidases; Glucosidases; Glucosylceramides; Glucosyltransferases; Glucuronidase; Glycosphingolipids; Kidney; Kinetics; Liver; Mice; Mice, Inbred ICR; Morpholines; Organ Specificity; Reference Values; Sphingomyelin Phosphodiesterase | 1991 |
Inhibition of sphingolipid biosynthesis decreases phosphorylated ERK2 in LLC-PK1 cells.
Topics: Acyltransferases; Animals; Apoptosis; Cell Division; Cycloserine; Enzyme Inhibitors; Fatty Acids, Monounsaturated; Fumonisins; Glucosyltransferases; LLC-PK1 Cells; Mitogen-Activated Protein Kinase 1; Morpholines; Oxidoreductases; Phosphorylation; Serine C-Palmitoyltransferase; Sphingolipids; Swine | 2005 |